1
|
López-Sánchez J, Esteban C, Iglesias MJ, González LM, Quiñones JE, González-Muñoz JI, Tabernero G, Iglesias RA, Fraile P, Muñoz-González JI, Muñoz-Bellvís L. Factors affecting diabetic patient's long-term quality of life after simultaneous pancreas-kidney transplantation: a single-center analysis. Langenbecks Arch Surg 2021; 406:873-882. [PMID: 33416988 DOI: 10.1007/s00423-020-02059-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2020] [Accepted: 12/09/2020] [Indexed: 10/22/2022]
Abstract
PURPOSE Pancreas transplantation (PT) is one of the few ways to restore euglycemia within diabetic patients; however, the high morbidity caused by surgical complications and the need for immunosuppressive therapy has raised controversy about PT improving the health-related quality-of-life (HRQoL). The aim of this study is to assess the long-term (≥ 5 years after PT) HRQoL and to identify the factors affecting it. METHODS A single-center, cross-sectional study of 49 sequential PT was performed. All patients conducted a telephone interview to fulfill the modification of Medical Outcome Health Survey Short Form questionnaire (SF-36v2) and were compared to similar post-PT studies from the literature. RESULTS Patients with a history of replacement renal therapy (RRT) or neuropathy undergoing a PT were associated to a worse bodily pain (P = 0.03) and physical function (P = 0.04), respectively, whereas those with retinopathy showed an improved Role Emotional (P = 0.04). Multivariate analysis revealed the presence of RRT as the only independent prognostic factor for a worse bodily pain [relative risk = 3.9; 95% confidence interval (1.1-14.6)], (P = 0.04). Furthermore, nearly all PT recipients (91.8%) claimed an overall better health than prior to PT. CONCLUSION Our study confirms that PT recipients' HRQoL improves after PT, showing similar HRQoL scores across different populations and suggests that patients in predialysis could benefit from an improved HRQoL if transplanted on the early stages of the disease.
Collapse
Affiliation(s)
- Jaime López-Sánchez
- Department of General and Gastrointestinal Surgery, Pancreas Transplant Program, Hospital Universitario de Salamanca, Salamanca, Spain.,Biomedical Research Institute of Salamanca (IBSAL), Universidad de Salamanca, Salamanca, Spain
| | - Carmen Esteban
- Department of General and Gastrointestinal Surgery, Pancreas Transplant Program, Hospital Universitario de Salamanca, Salamanca, Spain.,Biomedical Research Institute of Salamanca (IBSAL), Universidad de Salamanca, Salamanca, Spain
| | - Manuel J Iglesias
- Department of General and Gastrointestinal Surgery, Pancreas Transplant Program, Hospital Universitario de Salamanca, Salamanca, Spain.,Biomedical Research Institute of Salamanca (IBSAL), Universidad de Salamanca, Salamanca, Spain
| | - Luis M González
- Department of General and Gastrointestinal Surgery, Pancreas Transplant Program, Hospital Universitario de Salamanca, Salamanca, Spain.,Biomedical Research Institute of Salamanca (IBSAL), Universidad de Salamanca, Salamanca, Spain
| | - José E Quiñones
- Department of General and Gastrointestinal Surgery, Pancreas Transplant Program, Hospital Universitario de Salamanca, Salamanca, Spain.,Biomedical Research Institute of Salamanca (IBSAL), Universidad de Salamanca, Salamanca, Spain
| | - Juan I González-Muñoz
- Department of General and Gastrointestinal Surgery, Pancreas Transplant Program, Hospital Universitario de Salamanca, Salamanca, Spain.,Biomedical Research Institute of Salamanca (IBSAL), Universidad de Salamanca, Salamanca, Spain
| | - Guadalupe Tabernero
- Department of Nephrology, Hospital Universitario de Salamanca, Salamanca, Spain
| | - Rosa A Iglesias
- Department of Endocrinology, Hospital Universitario de Salamanca, Salamanca, Spain
| | - Pilar Fraile
- Department of Nephrology, Hospital Universitario de Salamanca, Salamanca, Spain
| | - Javier I Muñoz-González
- Biomedical Research Institute of Salamanca (IBSAL), Universidad de Salamanca, Salamanca, Spain.,Cancer Research Center (IBMCC, USAL-CSIC), Department of Medicine and Cytometry Service (NUCLEUS), Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Universidad de Salamanca, Salamanca, Spain
| | - Luis Muñoz-Bellvís
- Department of General and Gastrointestinal Surgery, Pancreas Transplant Program, Hospital Universitario de Salamanca, Salamanca, Spain. .,Biomedical Research Institute of Salamanca (IBSAL), Universidad de Salamanca, Salamanca, Spain. .,Department of Surgery, Hospital Universitario de Salamanca, Paseo San Vicente, 88-132, 37007, Salamanca, Spain.
| |
Collapse
|
2
|
Yu H, Chen Y, Kong H, He Q, Sun H, Bhugul PA, Zhang Q, Chen B, Zhou M. The rat pancreatic body tail as a source of a novel extracellular matrix scaffold for endocrine pancreas bioengineering. J Biol Eng 2018; 12:6. [PMID: 29719565 PMCID: PMC5923185 DOI: 10.1186/s13036-018-0096-5] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/27/2017] [Accepted: 03/19/2018] [Indexed: 12/28/2022] Open
Abstract
Background Regenerative medicine and tissue engineering are promising approaches for organ transplantation. Extracellular matrix (ECM) based scaffolds obtained through the decellularization of natural organs have become the preferred platform for organ bioengineering. In the field of pancreas bioengineering, acellular scaffolds from different animals approximate the biochemical, spatial and vascular relationships of the native extracellular matrix and have been proven to be a good platform for recellularization and in vitro culture. However, artificial endocrine pancreases based on these whole pancreatic scaffolds have a critical flaw, specifically their difficult in vivo transplantation, and connecting their vessels to the recipient is a major limitation in the development of pancreatic tissue engineering. In this study, we focus on preparing a novel acellular extracellular matrix scaffold derived from the rat pancreatic body tail (pan-body-tail ECM scaffold). Results Several analyses confirmed that our protocol effectively removes cellular material while preserving ECM proteins and the native vascular tree. DNA quantification demonstrated an obvious reduction of DNA compared with that of the natural organ (from 931.9 ± 267.8 to 11.7 ± 3.6 ng/mg, P < 0.001); the retention of the sGAG in the decellularized pancreas (0.878 ± 0.37) showed no significant difference from the natural pancreas (0.819 ± 0.1) (P > 0.05). After transplanted with the recellularized pancreas, fasting glucose levels declined to 9.08 ± 2.4 mmol/l within 2 h of the operation, and 8 h later, they had decreased to 4.7 ± 1.8 mmol/l (P < 0.05). Conclusions The current study describes a novel pancreatic ECM scaffold prepared from the rat pancreatic body tail via perfusion through the left gastric artery. We further showed the pioneering possibility of in vivo circulation-connected transplantation of a recellularized pancreas based on this novel scaffold. By providing such a promising pancreatic ECM scaffold, the present study might represent a key improvement and have a positive impact on endocrine pancreas bioengineering.
Collapse
Affiliation(s)
- Huajun Yu
- 1Department of Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325035 China
| | - Yunzhi Chen
- 1Department of Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325035 China
| | - Hongru Kong
- 1Department of Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325035 China
| | - Qikuan He
- 1Department of Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325035 China
| | - Hongwei Sun
- 1Department of Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325035 China
| | - Pravin Avinash Bhugul
- 1Department of Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325035 China
| | - Qiyu Zhang
- 1Department of Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325035 China
| | - Bicheng Chen
- 1Department of Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325035 China.,Key Laboratory of Diagnosis and Treatment of Severe Hepato-Pancreatic Diseases of Zhejiang Province, Zhejiang Provincial Top Key Discipline in Surgery, Wenzhou, China
| | - Mengtao Zhou
- 1Department of Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325035 China.,Key Laboratory of Diagnosis and Treatment of Severe Hepato-Pancreatic Diseases of Zhejiang Province, Zhejiang Provincial Top Key Discipline in Surgery, Wenzhou, China
| |
Collapse
|
3
|
3D Culture of MIN-6 Cells on Decellularized Pancreatic Scaffold: In Vitro and In Vivo Study. BIOMED RESEARCH INTERNATIONAL 2015; 2015:432645. [PMID: 26688810 PMCID: PMC4672115 DOI: 10.1155/2015/432645] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 06/17/2015] [Revised: 08/28/2015] [Accepted: 09/01/2015] [Indexed: 12/11/2022]
Abstract
Type 1 diabetes is an autoimmune disease which is due to the lack of β cells. The ideal therapy to cure the disease is pancreas transplantation, but its application is confined to a limited number of people due to the shortage of organ and the need for life-long immunosuppression. Regenerative medicine methods such as a tissue engineered pancreas seem to provide a useful method. In order to construct a microenvironment similar to the native pancreas that is suitable for not only cell growth but also cellular function exertion, a decellularized mouse pancreas was used as a natural 3D scaffold in this experiment. MIN-6 β cells were planted in the bioscaffold. The cell engraftment was verified by HE staining and SEM. Immunostaining procedures were performed to confirm the normal function of the engrafted cells. qRT-PCR demonstrated that insulin gene expression of the recellularized pancreas was upregulated compared with conventional plate-cultured cells. In vivo experiment was also accomplished to further evaluate the function of the recellularized bioscaffold and the result was inspiring. And beyond doubt this will bring new hope for type 1 diabetic patients.
Collapse
|
4
|
Clinical Practice Guideline on management of patients with diabetes and chronic kidney disease stage 3b or higher (eGFR <45 mL/min). Nephrol Dial Transplant 2015; 30 Suppl 2:ii1-142. [PMID: 25940656 DOI: 10.1093/ndt/gfv100] [Citation(s) in RCA: 96] [Impact Index Per Article: 10.7] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
|
5
|
Salvatori M, Katari R, Patel T, Peloso A, Mugweru J, Owusu K, Orlando G. Extracellular Matrix Scaffold Technology for Bioartificial Pancreas Engineering: State of the Art and Future Challenges. J Diabetes Sci Technol 2014; 8:159-169. [PMID: 24876552 PMCID: PMC4454093 DOI: 10.1177/1932296813519558] [Citation(s) in RCA: 40] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
Emergent technologies in regenerative medicine may soon overcome the limitations of conventional diabetes therapies. Collaborative efforts across the subfields of stem cell technology, islet encapsulation, and biomaterial carriers seek to produce a bioengineered pancreas capable of restoring endocrine function in patients with insulin-dependent diabetes. These technologies rely on a robust understanding of the extracellular matrix (ECM), the supportive 3-dimensional network of proteins necessary for cellular attachment, proliferation, and differentiation. Although these functions can be partially approximated by biosynthetic carriers, novel decellularization protocols have allowed researchers to discover the advantages afforded by the native pancreatic ECM. The native ECM has proven to be an optimal platform for recellularization and whole-organ pancreas bioengineering, an exciting new field with the potential to resolve the dire shortage of transplantable organs. This review seeks to contextualize recent findings, discuss current research goals, and identify future challenges of regenerative medicine as it applies to diabetes management.
Collapse
Affiliation(s)
| | - Ravi Katari
- Wake Forest School of Medicine, Winston-Salem, NC, USA
| | - Timil Patel
- Wake Forest School of Medicine, Winston-Salem, NC, USA
| | - Andrea Peloso
- Wake Forest School of Medicine, Winston-Salem, NC, USA Department of Surgery, School of Medicine, University of Pavia, Pavia, Italy
| | - Jon Mugweru
- Wake Forest School of Medicine, Winston-Salem, NC, USA
| | - Kofi Owusu
- Wake Forest School of Medicine, Winston-Salem, NC, USA
| | | |
Collapse
|
6
|
Abstract
For many patients with type 1 diabetes mellitus and selected patients with type 2 diabetes mellitus, a successful pancreas transplant is the only definitive long-term treatment that both restores euglycaemia without the risk of severe hypoglycaemia and prevents, halts or reverses secondary complications. These benefits come at the cost of major surgery and lifelong immunosuppression. Nevertheless, pancreas transplants are safe and effective, with patient survival rates currently >95% at 1 year and >88% at 5 years; graft survival rates are almost 85% at 1 year and >60% at 5 years. The estimated half-life of a pancreas graft is now 7-14 years. The improvements in graft survival are attributable to considerable reductions in technical failures and in immunologic graft losses. Pancreas recipients have reduced mortality compared with waiting candidates or patients with diabetes mellitus who undergo a kidney transplant alone. Pancreas transplants should be more frequently offered to nonuraemic patients with brittle diabetes mellitus to prevent the development of secondary diabetic complications and to avoid the need for a kidney transplant. Although the results of islet transplantation have also improved, islet recipients rarely maintain long-term insulin independence despite the use of multiple organ donor pancreases. Pancreas transplants and islet transplants should be considered complementary, not mutually exclusive, procedures that are chosen on the basis of the individual patient's surgical risk.
Collapse
Affiliation(s)
- Rainer W G Gruessner
- Department of Surgery, University of Arizona, 1501 N. Campbell Avenue, Room 4410, PO Box 245066, Tucson, AZ 85724, USA. rgruessner@ surgery.arizona.edu
| | | |
Collapse
|
7
|
Mirmalek-Sani SH, Orlando G, McQuilling JP, Pareta R, Mack DL, Salvatori M, Farney AC, Stratta RJ, Atala A, Opara EC, Soker S. Porcine pancreas extracellular matrix as a platform for endocrine pancreas bioengineering. Biomaterials 2013; 34:5488-95. [PMID: 23583038 DOI: 10.1016/j.biomaterials.2013.03.054] [Citation(s) in RCA: 86] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/25/2012] [Accepted: 03/15/2013] [Indexed: 01/11/2023]
Abstract
Emergent technologies of regenerative medicine have the potential to overcome the limitations of organ transplantation by supplying tissues and organs bioengineered in the laboratory. Pancreas bioengineering requires a scaffold that approximates the biochemical, spatial and vascular relationships of the native extracellular matrix (ECM). We describe the generation of a whole organ, three-dimensional pancreas scaffold using acellular porcine pancreas. Imaging studies confirm that our protocol effectively removes cellular material while preserving ECM proteins and the native vascular tree. The scaffold was seeded with human stem cells and porcine pancreatic islets, demonstrating that the decellularized pancreas can support cellular adhesion and maintenance of cell functions. These findings advance the field of regenerative medicine towards the development of a fully functional, bioengineered pancreas capable of establishing and sustaining euglycemia and may be used for transplantation to cure diabetes mellitus.
Collapse
|
8
|
Abstract
INTRODUCTION Diabetes mellitus is a spectrum of diseases characterized by the absence of glycemic control and the development of secondary complications. Type 1 diabetes (insulin-dependent) accounts for a minority of cases, but it usually presents in younger age groups. This disease significantly affects quality of life. METHODS We retrospectively reviewed the cases of pancreas transplantation performed at University of Texas, Houston, from February 2008 to August 2009. All patients received immunosuppression induction with thymoglobulin (1.5 mg/kg). We used 3 drugs for maintenance: tacrolimus, mycophenolic acid, and prednisone. All patients received cytomegalovirus prophylaxis. RESULTS We transplanted 54 organs in 29 patients with type 1 diabetes mellitus. The mean patient age was 42 years. Patients had diabetes mellitus type 1 for an average of 28.82 years and were on dialysis for an average of 2 years. Nineteen patients were male (65%). Complications ensued in 68% of cases (20 patients), 9 of which required surgical exploration (31%). We lost 3 pancreatic allografts. DISCUSSION Pancreas transplant recipients constitute a unique population with a high risk of complications in the acute setting. During the first 3 months after simultaneous pancreas-kidney transplantation the relative mortality risk is increased but after a year it has clear advantage over diabetic patients on dialysis waiting for a transplant. To date, 26 patients have functional pancreatic allografts and 29 are dialysis-free. Pancreas transplantation is a challenging procedure. Surgeons must be prepared to aggressively manage the possible complications.
Collapse
Affiliation(s)
- A Cicero
- University of Texas, Houston, Houston, Texas, USA.
| | | |
Collapse
|
9
|
|
10
|
Daga Ruiz D, Fernández Aguirre C, Segura González F, Carballo Ruiz M. [Indications and long-term outcomes for solid organ transplant. Quality of life in solid organ transplant recipients]. Med Intensiva 2009; 32:296-303. [PMID: 18601837 DOI: 10.1016/s0210-5691(08)70957-4] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Abstract
Organ transplant constitutes one of the most encouraging advances in the history of the medicine. The organ transplants that were a distant challenge in the seventies currently are a routine procedure in the medical practice that has contributed to extending survival and quality of life in the general population. Spain has reached the highest rate for donation and transplants per one million inhabitants worldwide, this extraordinary health care work being a combined achievement of Spanish Health Care System. The objective of this article is to review the indications of solid organ transplants and their long-term outcomes, evaluating the impact on the health-related quality of life in solid organ transplant recipients.
Collapse
Affiliation(s)
- D Daga Ruiz
- Servicio de Cuidados Críticos y Urgencias, Coordinación de Trasplantes, Hospital Universitario Virgen de la Victoria, Málaga, España.
| | | | | | | |
Collapse
|
11
|
Abstract
PURPOSE OF REVIEW Pancreas transplantation has emerged as an effective treatment for patients with diabetes mellitus, especially those with established end-stage renal disease. Surgical and immunosuppressive advances have significantly improved allograft survival. With more recipients enjoying normoglycemia for longer periods of time, the opportunity to study more closely the effects of pancreas transplantation has arisen. This review will focus on these long-term benefits. RECENT FINDINGS The field of pancreas transplantation has been limited by a lack of randomized, controlled trials and relatively poor graft survival rates historically, however we can still glean many important points from the existing literature. The procedure reduces mortality compared with diabetic kidney transplant recipients and waitlisted patients. Improvements in diabetic nephropathy and retinopathy have also been demonstrated. Pancreas transplantation can improve cardiovascular risk profiles, improve cardiac function and decrease cardiovascular events. Lastly, improvements in diabetic neuropathy and quality of life can result from pancreas transplantation. SUMMARY Pancreas transplantation remains the most effective method to establish durable normoglycemia for patients with diabetes mellitus. Well designed clinical studies to assess outcomes and adverse events will be of paramount importance in providing optimal care to patients with diabetes mellitus.
Collapse
|
12
|
Abstract
This research investigated patient satisfaction with heart transplantation (HT) 6 months after surgery. The authors explored whether HT patients would make the decision to have HT again and examined medical, psychosocial, and demographic factors associated with satisfaction or dissatisfaction in 257 HT recipients. Nonparametric statistics were used. Satisfaction with HT could be rated from 1 (not satisfied) to 10 (very satisfied). Eighty-seven percent of the patients were highly satisfied with HT 6 months after surgery (ratings of 8-10); 1% rated their satisfaction as low (1-3), and 12% rated it as moderate (4-7). Factors associated with less satisfaction with HT were: more symptom distress, greater disability, more stress, poor coping ability, feeling that the interventions of the HT team were not very helpful, less life satisfaction, and lower quality of life. Ninety-three percent indicated that they either definitely or probably would decide to have HT again; 7% responded "probably not" or "not sure." Factors associated with a negative perception of having another HT were: poor coping ability, less life satisfaction, lower quality of life, being male, and being married.
Collapse
|
13
|
Hakim NS. Whole organ pancreas transplantation. ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY 2006; 574:95-105. [PMID: 16836244 DOI: 10.1007/0-387-29512-7_11] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/10/2023]
Affiliation(s)
- Nadey S Hakim
- Transplant Unit, St Mary's Hospital, Praed Street, London W2 1NY, UK
| |
Collapse
|
14
|
Maia FFR, Araújo LR. Transplante de pâncreas na síndrome de Mauriac: evolução clínica e laboratorial após um ano de acompanhamento. ACTA ACUST UNITED AC 2005; 49:455-9. [PMID: 16544002 DOI: 10.1590/s0004-27302005000300019] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
O transplante de pâncreas tem se mostrado método eficaz no tratamento do diabetes mellitus tipo 1 (DM1) em casos selecionados, com redução da necessidade diária de insulina e normalização da glico-hemoglobina (A1c). Não há conhecimento, ainda, sobre o efeito do transplante de pâncreas em pacientes com síndrome de Mauriac (SM). Apresentamos um caso de SM refratário ao tratamento clínico instituído (insulinoterapia intensiva, atividade física programada, acompanhamento psicológico e nutricional), com persistência de níveis de glicemia de jejum e A1c continuamente elevados, dislipidemia e IGF-1 (fator de crescimento insulina símile) reduzido, sendo indicado o transplante pancreático. Após 1 ano do transplante de pâncreas total, o paciente permanecia assintomático, insulino-independente, com glicemia de jejum adequada (<110mg/dl), normalização do perfil lipídico e de IGF-1, com redução importante da A1c (4,6%), melhora da auto-estima e maior qualidade de vida para o paciente. O transplante de pâncreas mostrou-se método eficaz no controle da SM, com reversão importante dos parâmetros clínico-laboratoriais nesse caso. Objetiva-se divulgar o primeiro caso de SM controlado com transplante de pâncreas descrito na literatura médica indexada, como alternativa terapêutica nesse grupo de pacientes.
Collapse
Affiliation(s)
- Frederico F R Maia
- Clínica Médica, Hospital Universitário São José, Faculdade de Ciências Médicas de Minas Gerais, Belo Horizonte, MG.
| | | |
Collapse
|
15
|
Drognitz O, Benz S, Pfeffer F, Fischer C, Makowiec F, Schareck W, Hopt UT. Long-term follow-up of 78 simultaneous pancreas-kidney transplants at a single-center institution in Europe. Transplantation 2005; 78:1802-8. [PMID: 15614154 DOI: 10.1097/01.tp.0000147789.06043.a6] [Citation(s) in RCA: 45] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
BACKGROUND The objective of this study was to determine the long-term results after simultaneous pancreas-kidney transplantation (SPK) at a single-center institution in Europe. PATIENTS AND METHODS Seventy-eight consecutive patients with insulin-dependent diabetes mellitus and end-stage nephropathy were followed for a median of 7 years after SPK. Immunosuppressive protocol consisted of cyclosporine A, azathioprine, prednisone, and antithymocyte globulin. Multivariate Cox proportional hazard model was used to investigate the impact of different putative risk factors on long-term patient survival. Health-related quality of life was assessed by a validated questionnaire (SF-36). RESULTS Patient survival at 5 and 10 years was 81% and 67%, respectively. Pancreas function rate was 73% and 60% and kidney function 67% and 44%, respectively. In multivariate analysis, preexisting myocardial infarction (relative risk [RR] 5.1, 95% confidence interval [CI] 1.5-16.6) and amputation (RR 3.7, 95% CI 1.1-12.9) were strongly associated with a diminished long-term patient survival. Analysis of patients with long-term functioning pancreas and kidney grafts revealed excellent results for quality of life posttransplant that were comparable with average scores of the normal German population. CONCLUSIONS This series representing the largest experience with long-term follow-up in Europe confirms an excellent long-term survival and an exceptional quality of life after SPK.
Collapse
Affiliation(s)
- Oliver Drognitz
- University of Freiburg, Department of General and Visceral Surgery, Freiburg, Germany.
| | | | | | | | | | | | | |
Collapse
|
16
|
Abstract
Pancreas transplantation continues to evolve as a strategy in the management of diabetes mellitus. The first combined pancreas-kidney transplant was reported in 1967, but pancreas transplant now represents a number of procedures, each with different indications, risks, benefits, and outcomes. This review will summarize these procedures, including their risks and outcomes in comparison to kidney transplantation alone, and how or if they affect the consequences of diabetes: hyperglycemia, hypoglycemia, and microvascular and macrovascular complications. In addition, the new risks introduced by immunosuppression will be reviewed, including infections, cancer, osteoporosis, reproductive function, and the impact of immunosuppression medications on blood pressure, lipids, and glucose tolerance. It is imperative that an endocrinologist remain involved in the care of the pancreas transplant recipient, even when glucose is normal, because of the myriad of issues encountered post transplant, including ongoing management of diabetic complications, prevention of bone loss, and screening for failure of the pancreas graft with reinstitution of treatment when indicated. Although long-term patient and graft survival have improved greatly after pancreas transplant, a multidisciplinary team is needed to maximize long-term quality, as well as quantity, of life for the pancreas transplant recipient.
Collapse
Affiliation(s)
- Jennifer L Larsen
- Section of Diabetes, Endocrinology, and Metabolism, Department of Internal Medicine, 983020 Nebraska Medical Center, Omaha, Nebraska 69198-3020, USA.
| |
Collapse
|
17
|
Abstract
In the face of a rising incidence of diabetes, pancreatic transplantation seems to be the only treatment capable of normalizing glycosylated hemoglobin and stabilizing or improving the complications of diabetes. To date, more than 19,000 pancreatic transplantations have been done worldwide. Surgical indications must take into account the constraints and risks specific to the diabetic illness, the risks of a complex surgical procedure, and the absolute necessity for long term immunosuppression. Combined kidney/pancreas transplantation is the most common procedure (90% of cases) and is the most effective treatment for renal insufficiency due to diabetes. Results have improved significantly over the last ten Years due to improvements in the surgical technique and to improvement of immunosuppressive regimens. Results are at least as good and perhaps better than those achieved in the transplantation of other solid organs; patient survival, renal graft survival, and pancreatic graft survival are respectively 95%, 92%, and 85% at one Year. Results of pancreatic transplantation alone have improved and now seem equal to those of combined organ transplantation. Transplantation seems to be cost-effective in the overall care of advanced diabetes, particularly in those patients on chronic dialysis or having degenerative complications.
Collapse
Affiliation(s)
- J P Duffas
- Service de Chirurgie Générale et Digestive, Hôpital Rangueil - Toulouse.
| |
Collapse
|
18
|
Sutherland DER, Gruessner A, Hering BJ. Beta-cell replacement therapy (pancreas and islet transplantation) for treatment of diabetes mellitus: an integrated approach. Endocrinol Metab Clin North Am 2004; 33:135-48, x. [PMID: 15053899 DOI: 10.1016/s0889-8529(03)00099-9] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Affiliation(s)
- David E R Sutherland
- Department of Surgery, University of Minnesota, 420 Delaware Street SE, Box 280, Minneapolis, MN 55455, USA.
| | | | | |
Collapse
|
19
|
Abstract
Type 1 diabetes affects over 1 million persons in the United States, with over 30,000 new cases diagnosed annually. Transplantation of new insulin-producing b cells, in the form of the whole pancreas or isolated islets, has been shown to ameliorate the disease by eliminating the need for exogenous insulin and normalizing glycosylated hemoglobin levels. Islet transplants are a particularly attractive form of therapy because they are a minimally invasive procedure and are more likely to be scaled-up to treat the large numbers of people affected by diabetes. Currently, only a handful of programs have been successful in the endeavor. Nevertheless, the early clinical experience strongly demonstrates that islet transplantation is an effective treatment strategy in select patients with type 1 diabetes. To scale up this therapy and use it earlier in the disease and for more people, the shortage of suitable donor tissue must be solved and the requirement of lifelong immunosuppression must be minimized.
Collapse
Affiliation(s)
- Dixon B Kaufman
- Feinberg School of Medicine, Northwestern University, Galter Pavilion, #17-200, 675 N. St. Clair Street, Chicago, IL 60611, USA.
| | | |
Collapse
|
20
|
Abstract
Kidney transplantation is preferred over dialysis for management of end-stage renal disease complicating type I or type 2 diabetes, for those who are eligible. Simultaneous pancreas-kidney (SPK) or pancreas after kidney transplantation (PAK) is an important alternative to kidney transplantation alone for type I diabetes patients if the patient is able to withstand the additional risks of these procedures, because of the benefits of glucose control on other diabetic complications. Pancreas transplantation alone (PTA) is most useful for the treatment of debilitating, frequent hypoglycemia complicating type I diabetes, if renal function is adequate. One-year pancreas graft survival is best after SPK (82%) but has significantly improved after both PAK (74%) and PTA (76%). The I-year kidney graft and patient survival rates after SPK are similar to kidney transplantation alone. Pancreas transplantation normalizes glucose beyond what can be achieved with insulin therapy and has been shown to decrease progression of or improve most, if not all, diabetic end-organ complications using current immunosuppression regimens. However, the diabetologist and endocrinologist should remain involved in the care of the pancreas or kidney transplant recipient for treatment of vascular disease risk factors such as dyslipidemia, surveillance of other diabetic complications including foot ulcers, surveillance and treatment of bone loss, and management of hyperglycemia if it recurs.
Collapse
Affiliation(s)
- Jennifer Larsen
- Department of Internal Medicine, 983020 Nebraska Medical Center, Omaha, NE 69198-3020, USA.
| | | | | |
Collapse
|
21
|
Hariharan S, Pirsch JD, Lu CY, Chan L, Pesavento TE, Alexander S, Bumgardner GL, Baasadona G, Hricik DE, Pescovitz MD, Rubin NT, Stratta RJ. Pancreas after kidney transplantation. J Am Soc Nephrol 2002; 13:1109-1118. [PMID: 11912273 DOI: 10.1681/asn.v1341109] [Citation(s) in RCA: 38] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022] Open
Affiliation(s)
- Sundaram Hariharan
- *Division of Nephrology, Medical College of Wisconsin, Milwaukee, Wisconsin; Department of Transplant Surgery, University of Wisconsin, Madison, Wisconsin; Division of Nephrology, University of Texas, Dallas, Texas; Division of Nephrology, University of Colorado, Denver, Colorado; Division of Nephrology, Ohio State University, Columbus, Ohio; Division of Pediatric Nephrology, Stanford University, Stanford, California; #Department of Transplant Surgery, Yale University, New Haven, Connecticut; **Division of Nephrology, Case Western Reserve University, Cleveland, Ohio; Department of Transplant Surgery, Indiana University, Indianapolis, Indiana; Division of Nephrology, Massachusetts General Hospital, Boston, Massachusetts; and Department of Transplant Surgery, Wake Forest University, Winston-Salem, North Carolina
| | - John D Pirsch
- *Division of Nephrology, Medical College of Wisconsin, Milwaukee, Wisconsin; Department of Transplant Surgery, University of Wisconsin, Madison, Wisconsin; Division of Nephrology, University of Texas, Dallas, Texas; Division of Nephrology, University of Colorado, Denver, Colorado; Division of Nephrology, Ohio State University, Columbus, Ohio; Division of Pediatric Nephrology, Stanford University, Stanford, California; #Department of Transplant Surgery, Yale University, New Haven, Connecticut; **Division of Nephrology, Case Western Reserve University, Cleveland, Ohio; Department of Transplant Surgery, Indiana University, Indianapolis, Indiana; Division of Nephrology, Massachusetts General Hospital, Boston, Massachusetts; and Department of Transplant Surgery, Wake Forest University, Winston-Salem, North Carolina
| | - Christopher Y Lu
- *Division of Nephrology, Medical College of Wisconsin, Milwaukee, Wisconsin; Department of Transplant Surgery, University of Wisconsin, Madison, Wisconsin; Division of Nephrology, University of Texas, Dallas, Texas; Division of Nephrology, University of Colorado, Denver, Colorado; Division of Nephrology, Ohio State University, Columbus, Ohio; Division of Pediatric Nephrology, Stanford University, Stanford, California; #Department of Transplant Surgery, Yale University, New Haven, Connecticut; **Division of Nephrology, Case Western Reserve University, Cleveland, Ohio; Department of Transplant Surgery, Indiana University, Indianapolis, Indiana; Division of Nephrology, Massachusetts General Hospital, Boston, Massachusetts; and Department of Transplant Surgery, Wake Forest University, Winston-Salem, North Carolina
| | - Laurence Chan
- *Division of Nephrology, Medical College of Wisconsin, Milwaukee, Wisconsin; Department of Transplant Surgery, University of Wisconsin, Madison, Wisconsin; Division of Nephrology, University of Texas, Dallas, Texas; Division of Nephrology, University of Colorado, Denver, Colorado; Division of Nephrology, Ohio State University, Columbus, Ohio; Division of Pediatric Nephrology, Stanford University, Stanford, California; #Department of Transplant Surgery, Yale University, New Haven, Connecticut; **Division of Nephrology, Case Western Reserve University, Cleveland, Ohio; Department of Transplant Surgery, Indiana University, Indianapolis, Indiana; Division of Nephrology, Massachusetts General Hospital, Boston, Massachusetts; and Department of Transplant Surgery, Wake Forest University, Winston-Salem, North Carolina
| | - Todd E Pesavento
- *Division of Nephrology, Medical College of Wisconsin, Milwaukee, Wisconsin; Department of Transplant Surgery, University of Wisconsin, Madison, Wisconsin; Division of Nephrology, University of Texas, Dallas, Texas; Division of Nephrology, University of Colorado, Denver, Colorado; Division of Nephrology, Ohio State University, Columbus, Ohio; Division of Pediatric Nephrology, Stanford University, Stanford, California; #Department of Transplant Surgery, Yale University, New Haven, Connecticut; **Division of Nephrology, Case Western Reserve University, Cleveland, Ohio; Department of Transplant Surgery, Indiana University, Indianapolis, Indiana; Division of Nephrology, Massachusetts General Hospital, Boston, Massachusetts; and Department of Transplant Surgery, Wake Forest University, Winston-Salem, North Carolina
| | - Steven Alexander
- *Division of Nephrology, Medical College of Wisconsin, Milwaukee, Wisconsin; Department of Transplant Surgery, University of Wisconsin, Madison, Wisconsin; Division of Nephrology, University of Texas, Dallas, Texas; Division of Nephrology, University of Colorado, Denver, Colorado; Division of Nephrology, Ohio State University, Columbus, Ohio; Division of Pediatric Nephrology, Stanford University, Stanford, California; #Department of Transplant Surgery, Yale University, New Haven, Connecticut; **Division of Nephrology, Case Western Reserve University, Cleveland, Ohio; Department of Transplant Surgery, Indiana University, Indianapolis, Indiana; Division of Nephrology, Massachusetts General Hospital, Boston, Massachusetts; and Department of Transplant Surgery, Wake Forest University, Winston-Salem, North Carolina
| | - Ginny L Bumgardner
- *Division of Nephrology, Medical College of Wisconsin, Milwaukee, Wisconsin; Department of Transplant Surgery, University of Wisconsin, Madison, Wisconsin; Division of Nephrology, University of Texas, Dallas, Texas; Division of Nephrology, University of Colorado, Denver, Colorado; Division of Nephrology, Ohio State University, Columbus, Ohio; Division of Pediatric Nephrology, Stanford University, Stanford, California; #Department of Transplant Surgery, Yale University, New Haven, Connecticut; **Division of Nephrology, Case Western Reserve University, Cleveland, Ohio; Department of Transplant Surgery, Indiana University, Indianapolis, Indiana; Division of Nephrology, Massachusetts General Hospital, Boston, Massachusetts; and Department of Transplant Surgery, Wake Forest University, Winston-Salem, North Carolina
| | - Giacomo Baasadona
- *Division of Nephrology, Medical College of Wisconsin, Milwaukee, Wisconsin; Department of Transplant Surgery, University of Wisconsin, Madison, Wisconsin; Division of Nephrology, University of Texas, Dallas, Texas; Division of Nephrology, University of Colorado, Denver, Colorado; Division of Nephrology, Ohio State University, Columbus, Ohio; Division of Pediatric Nephrology, Stanford University, Stanford, California; #Department of Transplant Surgery, Yale University, New Haven, Connecticut; **Division of Nephrology, Case Western Reserve University, Cleveland, Ohio; Department of Transplant Surgery, Indiana University, Indianapolis, Indiana; Division of Nephrology, Massachusetts General Hospital, Boston, Massachusetts; and Department of Transplant Surgery, Wake Forest University, Winston-Salem, North Carolina
| | - Donald E Hricik
- *Division of Nephrology, Medical College of Wisconsin, Milwaukee, Wisconsin; Department of Transplant Surgery, University of Wisconsin, Madison, Wisconsin; Division of Nephrology, University of Texas, Dallas, Texas; Division of Nephrology, University of Colorado, Denver, Colorado; Division of Nephrology, Ohio State University, Columbus, Ohio; Division of Pediatric Nephrology, Stanford University, Stanford, California; #Department of Transplant Surgery, Yale University, New Haven, Connecticut; **Division of Nephrology, Case Western Reserve University, Cleveland, Ohio; Department of Transplant Surgery, Indiana University, Indianapolis, Indiana; Division of Nephrology, Massachusetts General Hospital, Boston, Massachusetts; and Department of Transplant Surgery, Wake Forest University, Winston-Salem, North Carolina
| | - Mark D Pescovitz
- *Division of Nephrology, Medical College of Wisconsin, Milwaukee, Wisconsin; Department of Transplant Surgery, University of Wisconsin, Madison, Wisconsin; Division of Nephrology, University of Texas, Dallas, Texas; Division of Nephrology, University of Colorado, Denver, Colorado; Division of Nephrology, Ohio State University, Columbus, Ohio; Division of Pediatric Nephrology, Stanford University, Stanford, California; #Department of Transplant Surgery, Yale University, New Haven, Connecticut; **Division of Nephrology, Case Western Reserve University, Cleveland, Ohio; Department of Transplant Surgery, Indiana University, Indianapolis, Indiana; Division of Nephrology, Massachusetts General Hospital, Boston, Massachusetts; and Department of Transplant Surgery, Wake Forest University, Winston-Salem, North Carolina
| | - Nina T Rubin
- *Division of Nephrology, Medical College of Wisconsin, Milwaukee, Wisconsin; Department of Transplant Surgery, University of Wisconsin, Madison, Wisconsin; Division of Nephrology, University of Texas, Dallas, Texas; Division of Nephrology, University of Colorado, Denver, Colorado; Division of Nephrology, Ohio State University, Columbus, Ohio; Division of Pediatric Nephrology, Stanford University, Stanford, California; #Department of Transplant Surgery, Yale University, New Haven, Connecticut; **Division of Nephrology, Case Western Reserve University, Cleveland, Ohio; Department of Transplant Surgery, Indiana University, Indianapolis, Indiana; Division of Nephrology, Massachusetts General Hospital, Boston, Massachusetts; and Department of Transplant Surgery, Wake Forest University, Winston-Salem, North Carolina
| | - Robert J Stratta
- *Division of Nephrology, Medical College of Wisconsin, Milwaukee, Wisconsin; Department of Transplant Surgery, University of Wisconsin, Madison, Wisconsin; Division of Nephrology, University of Texas, Dallas, Texas; Division of Nephrology, University of Colorado, Denver, Colorado; Division of Nephrology, Ohio State University, Columbus, Ohio; Division of Pediatric Nephrology, Stanford University, Stanford, California; #Department of Transplant Surgery, Yale University, New Haven, Connecticut; **Division of Nephrology, Case Western Reserve University, Cleveland, Ohio; Department of Transplant Surgery, Indiana University, Indianapolis, Indiana; Division of Nephrology, Massachusetts General Hospital, Boston, Massachusetts; and Department of Transplant Surgery, Wake Forest University, Winston-Salem, North Carolina
| |
Collapse
|
22
|
Long-term effects of pancreatic transplantation on secondary complications of diabetes. Curr Opin Organ Transplant 2001. [DOI: 10.1097/00075200-200106000-00016] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
23
|
Sutherland DE, Gruessner RW, Dunn DL, Matas AJ, Humar A, Kandaswamy R, Mauer SM, Kennedy WR, Goetz FC, Robertson RP, Gruessner AC, Najarian JS. Lessons learned from more than 1,000 pancreas transplants at a single institution. Ann Surg 2001; 233:463-501. [PMID: 11303130 PMCID: PMC1421277 DOI: 10.1097/00000658-200104000-00003] [Citation(s) in RCA: 412] [Impact Index Per Article: 17.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
OBJECTIVE To determine outcome in diabetic pancreas transplant recipients according to risk factors and the surgical techniques and immunosuppressive protocols that evolved during a 33-year period at a single institution. SUMMARY BACKGROUND DATA Insulin-dependent diabetes mellitus is associated with a high incidence of management problems and secondary complications. Clinical pancreas transplantation began at the University of Minnesota in 1966, initially with a high failure rate, but outcome improved in parallel with other organ transplants. The authors retrospectively analyzed the factors associated with the increased success rate of pancreas transplants. METHODS From December 16, 1966, to March 31, 2000, the authors performed 1,194 pancreas transplants (111 from living donors; 191 retransplants): 498 simultaneous pancreas-kidney (SPK) and 1 simultaneous pancreas-liver transplant; 404 pancreas after kidney (PAK) transplants; and 291 pancreas transplants alone (PTA). The analyses were divided into five eras: era 0, 1966 to 1973 (n = 14), historical; era 1, 1978 to 1986 (n = 148), transition to cyclosporine for immunosuppression, multiple duct management techniques, and only solitary (PAK and PTA) transplants; era 2, 1986 to 1994 (n = 461), all categories (SPK, PAK, and PTA), predominantly bladder drainage for graft duct management, and primarily triple therapy (cyclosporine, azathioprine, and prednisone) for maintenance immunosuppression; era 3, 1994 to 1998 (n = 286), tacrolimus and mycophenolate mofetil used; and era 4, 1998 to 2000 (n = 275), use of daclizumab for induction immunosuppression, primarily enteric drainage for SPK transplants, pretransplant immunosuppression in candidates awaiting PTA. RESULTS Patient and primary cadaver pancreas graft functional (insulin-independence) survival rates at 1 year by category and era were as follows: SPK, era 2 (n = 214) versus eras 3 and 4 combined (n = 212), 85% and 64% versus 92% and 79%, respectively; PAK, era 1 (n = 36) versus 2 (n = 61) versus 3 (n = 84) versus 4 (n = 92), 86% and 17%, 98% and 59%, 98% and 76%, and 98% and 81%, respectively; in PTA, era 1 (n = 36) versus 2 (n = 72) versus 3 (n = 30) versus 4 (n = 40), 77% and 31%, 99% and 50%, 90% and 67%, and 100% and 88%, respectively. In eras 3 and 4 combined for primary cadaver SPK transplants, pancreas graft survival rates were significantly higher with bladder drainage (n = 136) than enteric drainage (n = 70), 82% versus 74% at 1 year (P =.03). Increasing recipient age had an adverse effect on outcome only in SPK recipients. Vascular disease was common (in eras 3 and 4, 27% of SPK recipients had a pretransplant myocardial infarction and 40% had a coronary artery bypass); those with no vascular disease had significantly higher patient and graft survival rates in the SPK and PAK categories. Living donor segmental pancreas transplants were associated with higher technically successful graft survival rates in each era, predominately solitary (PAK and PTA) in eras 1 and 2 and SPK in eras 3 and 4. Diabetic secondary complications were ameliorated in some recipients, and quality of life studies showed significant gains after the transplant in all recipient categories. CONCLUSIONS Patient and graft survival rates have significantly improved over time as surgical techniques and immunosuppressive protocols have evolved. Eventually, islet transplants will replace pancreas transplants for suitable candidates, but currently pancreas transplants can be applied and should be an option at all stages of diabetes. Early transplants are preferable for labile diabetes, but even patients with advanced complications can benefit.
Collapse
Affiliation(s)
- D E Sutherland
- Department of Surgery, University of Minnesota, Minneapolis, Minnesota 55455, USA.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Cundiff JD, Hovis SM, Pories WJ. Pancreatic transplantation. CURRENT SURGERY 2001; 58:165-173. [PMID: 11275236 DOI: 10.1016/s0149-7944(00)00418-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Affiliation(s)
- J D. Cundiff
- Brody School of Medicine at East Carolina University, Greenville, North Carolina, USA
| | | | | |
Collapse
|
25
|
Hathaway DK, Wicks MN, Cashion AK, Cowan PA, Milstead EJ, Gaber AO. Posttransplant improvement in heart rate variability correlates with improved quality of life. West J Nurs Res 2000; 22:749-68. [PMID: 11094577 DOI: 10.1177/01939450022044728] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
A prospective evaluation of 37 kidney and 20 kidney-pancreas transplant recipients was conducted to assess the relationship between pre- to posttransplant changes in heart rate variability (HRV) and quality of life (QoL). Assessments of 24-hour interbeat variability (pNN50 and rMSSD, SDNN, SDANN) and power spectral analysis of total, low (sympathetic), and high (parasympathetic) frequency components of HRV were performed. The Sickness Impact Profile was used to assess three dimensions of QoL (physical, psychosocial, and total functioning) prior to and at 6 months following transplantation. Changes in vagally mediated time domain measures of HRV were related to changes in physical and total functioning. Stronger correlations occurred between biobehavioral measures in kidney-pancreas recipients, with the strongest relationships occurring between changes in HRV frequency domain measures and changes in physical functioning. Findings indicate that changes in HRV and QoL are related, suggesting that interventions that enhance transplant recipients' HRV may also enhance their QoL.
Collapse
Affiliation(s)
- D K Hathaway
- College of Nursing, University of Tennessee, Memphis, USA
| | | | | | | | | | | |
Collapse
|
26
|
Abstract
Throughout 1997, nearly 10,000 pancreas transplants have been performed worldwide, with 88% being simultaneous kidney transplants (SKPT). The current 1 yr patient survival rate exceeds 90% and pancreas graft survival (complete insulin independence) rate exceeds 80% for SKPT, 70% for sequential pancreas after kidney transplant (PAKT), and 65% for pancreas transplant alone (PTA). According to registry data, rejection accounts for 32% of graft failures in the first year after pancreas transplantation. However, improvements are expected to continue with the evolution of treatment protocols. Most pancreas transplant centers employ quadruple drug immunosuppression with anti-lymphocyte induction with either a monoclonal or polyclonal antibody agent. In recent years, there has been an overall decline in the use of antibody induction therapy from 90% during the period 1987-1993 to 83% of pancreas transplants performed during 1994-1997. Maintenance immunosuppression is triple therapy consisting of a calcineurin inhibitor (cyclosporine or tacrolimus), corticosteroids, and an anti-metabolite (AZA or MMF). Prior to 1995, nearly all pancreas transplant recipients were managed with Sandimmune. In the last 2 yr, tacrolimus-based therapy has been used in approximately 20% of cases and a new microemulsion formulation of cyclosporine (Neoral) has replaced Sandimmune in contemporary post-transplant immunosuppression. In addition, MMF is replacing AZA as part of the standard immunosuppressive regimen after pancreas transplantation. At present, a number of centers are conducting various trials with new drug combinations including either Neoral or tacrolimus in combination with steroids and MMF with or without antibody induction therapy. From 1994 to 1997, the 1 yr rates of immunologic graft loss have decreased to 2% after SKPT, 9% after PAKT, and 16% after PTA. The current array of new immunosuppressive agents are providing more effective control of rejection and permitting solitary pancreas transplantation to become an accepted treatment option in diabetic patients without advanced complications. The apparent potency of new drug combinations has also resulted in a resurgence of interest in steroid withdrawal. Immunosuppressive strategies will continue to evolve in order to achieve effective control of rejection while minimizing injury to the allograft and risk to the patient. In addition, new regimens must not only address the issue of specific drug toxicities but also long-term economic, metabolic, and quality of life outcomes. Pancreas transplantation will remain an important alternative in the treatment of diabetic patients until other strategies are developed that can provide equal glycemic control with less immunosuppression and overall morbidity.
Collapse
Affiliation(s)
- R J Stratta
- Department of Surgery, University of Tennessee-Memphis 38163-2116, USA.
| |
Collapse
|
27
|
Hathaway DK, Wicks MN, Cashion AK, Cowan PA, Milstead EJ, Gaber AO. Heart rate variability and quality of life following kidney and pancreas-kidney transplantation. Transplant Proc 1999; 31:643-4. [PMID: 10083276 DOI: 10.1016/s0041-1345(98)01596-6] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- D K Hathaway
- Department of Acute Care Nursing, University of Tennessee, Memphis 38163, USA
| | | | | | | | | | | |
Collapse
|
28
|
Abstract
Through 1997, over 10,000 pancreas transplants have been performed world-wide, with 88% being simultaneous kidney-pancreas transplants (SKPTs). Current 1-year patient survival exceeds 90% and pancreas graft survival (complete insulin independence) exceeds 80% for SKPT, 70% for sequential pancreas after kidney transplant (PAKT), and 65% for pancreas transplant alone (PTA). According to Registry data, rejection accounts for 32% of graft failures in the first year after pancreas transplantation. However, improving outcomes are expected to continue with the evolution of treatment protocols. Most pancreas transplant centres employ quadruple drug immunosuppression with anti-lymphocyte induction, using either a monoclonal or polyclonal antibody agent. In recent years, there has been an overall decline in the use of antibody-induction therapy from 90% during 1987-93, to 83% of pancreas transplants performed during 1994-97. Maintenance immunosuppression is triple therapy consisting of a calcineurin inhibitor (cyclosporine or tacrolimus), corticosteroids, and an anti-metabolite such as azathioprine (AZA) or mycophenolate mofetil (MMF). Prior to 1995, nearly all pancreas transplant recipients were managed with Sandimmune. Since 1986, tacrolimus-based therapy has been used in approximately 20% of cases, and a new microemulsion formulation of cyclosporine (Neoral) has replaced Sandimmune in contemporary post-transplant immunosuppression. In addition, MMF is replacing AZA as part of the standard immunosuppressive regimen following pancreas transplantation. At present, a number of centres are conducting various trials with new drug combinations including either Neoral or tacrolimus in combination with steroids and MMF, with or without antibody-induction therapy. From 1994 to 1997, the 1-year rates of immunologic graft loss have decreased to 2% after SKPT, 9% after PAKT, and 16% after PTA. The current array of new immunosuppressive agents are providing more effective control of rejection and permitting solitary pancreas transplantation to become an accepted treatment option in diabetic patients without advanced complications. The apparent potency of new drug combinations has also resulted in a resurgence of interest in steroid withdrawal. Immunosuppressive strategies will continue to evolve to achieve effective control of rejection while minimizing injury to the allograft and risk to the patient. In addition, new regimens must not only address the issue of specific drug toxicities, but also long-term economic, metabolic, and quality of life outcomes. Pancreas transplantation will remain an important alternative in the treatment of diabetic patients until other strategies are developed that can provide equal glycaemic control with less immunosuppression and overall morbidity.
Collapse
Affiliation(s)
- R J Stratta
- Department of Surgery, University of Tennessee-Memphis 38163-2116, USA.
| |
Collapse
|
29
|
Korbutt GS, Warlock GL, Rajotte RV. Islet transplantation. ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY 1998; 426:397-410. [PMID: 9544300 DOI: 10.1007/978-1-4899-1819-2_53] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Affiliation(s)
- G S Korbutt
- Department of Surgery, Surgical-Medical Research Institute, University of Alberta, Edmonton
| | | | | |
Collapse
|
30
|
Secchi A, Martinenghi S, Castoldi R, Giudici D, Di Carlo V, Pozza G. Effects of pancreas transplantation on quality of life in type I diabetic patients undergoing kidney transplantation. Transplant Proc 1998; 30:339-42. [PMID: 9532068 DOI: 10.1016/s0041-1345(97)01296-7] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Affiliation(s)
- A Secchi
- Department of Internal Medicine, Scientific Institute San Raffaele, University of Milan, Italy
| | | | | | | | | | | |
Collapse
|
31
|
Painter PL, Luetkemeier MJ, Moore GE, Dibble SL, Green GA, Myll JO, Carlson LL. Health-related fitness and quality of life in organ transplant recipients. Transplantation 1997; 64:1795-800. [PMID: 9422422 DOI: 10.1097/00007890-199712270-00029] [Citation(s) in RCA: 72] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
BACKGROUND The purpose of this study was to describe the levels of health-related fitness and quality of life in a group of organ transplant recipients who participated in the 1996 U.S. Transplant Games. METHODS A total of 128 transplant recipients were selected on a first reply basis for testing. Subjects with the following organ types were tested: kidney (n=76), liver (n=16), heart (n=19), lung (n=6), pancreas/kidney (n=7), and bone marrow (n=4). Cardiorespiratory fitness (peak oxygen uptake) was measured using symptom-limited treadmill exercise tests with expired gas analysis. The percentage of body fat was measured using skinfold measurements, and the Medical Outcomes Short Form questionnaire (SF-36) was used to evaluate health-related quality of life. RESULTS Participants achieved near age-predicted cardiorespiratory fitness (94.7+/-32.5% of age-predicted levels). Scores on the SF-36 were near normal. The active subjects (76% of total sample) had significantly higher levels of peak VO2 and quality of life and a lower percentage of body fat compared with inactive subjects (P<0.01). CONCLUSIONS Although this is a highly select group which is not representative of the general transplant population, the data suggest that near-normal levels of physical functioning and quality of life are possible after transplantation and that those who participate in regular physical activity may achieve even higher levels.
Collapse
Affiliation(s)
- P L Painter
- University of California, San Francisco 94143, USA.
| | | | | | | | | | | | | |
Collapse
|
32
|
Kendall DM, Robertson RP. Pancreas and islet transplantation. Challenges for the twenty-first century. Endocrinol Metab Clin North Am 1997; 26:611-30. [PMID: 9314018 DOI: 10.1016/s0889-8529(05)70270-x] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
This article reviews both pancreas and islet transplantation in detail. The history of each procedure, the effects of these therapies on glucose metabolism, glucose counterregulation, and islet cell secretory function, as well as the challenges that result from each procedure are considered.
Collapse
Affiliation(s)
- D M Kendall
- Department of Internal Medicine, University of Minnesota, Minneapolis, USA
| | | |
Collapse
|
33
|
Königsrainer A, Mark W, Hechenleitner P, Klima G, Dietze O, Margreiter R. At what stage does pancreas allograft rejection become irreversible?: an experimental study. Transplantation 1997; 63:631-5. [PMID: 9075829 DOI: 10.1097/00007890-199703150-00003] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
BACKGROUND It is commonly believed that abnormal blood glucose levels indicate irreversible rejection. We were interested in determining the stage at which rejection remains reversible. METHODS A total of 54 Lewis rats were rendered diabetic with 55 mg/kg streptozocin and were then given a pancreas transplant from Brown Norway donors. Pancreatic juice was collected in a subcutaneous reservoir. All recipients received 15 mg/kg cyclosporine A (CsA) for 5 days. CsA was then discontinued for 2 days (n=7, group 1), 4 days (n=7, group 2), 6 days (n=9, group 3), 8 days (n=9, group 4), 9 days (n=11, group 5), and 10 days (n=11, group 6). Two animals of each group were euthanized at the end of the immunosuppressive-free interval, for histological assessment of the grade of rejection (G0, GI, GII, GIII). Rejection was treated with methylprednisolone (7 mg/kg body weight) and CsA (15 mg/kg body weight). The volume of pancreatic juice, together with juice cytology (C0, CI, CII) and blood glucose levels, was assessed daily. RESULTS Blood glucose remained normal throughout the observation period in animals with GI and GII rejection. The numbers of animals that became diabetic were as follows: 5 of 9 (group 4), 7 of 11 (group 5), and 8 of 11 (group 6). Decreased amounts of pancreatic juice were observed in all animals, except those in group 1. The histology returned to normal after anti-rejection therapy in four animals (57%) of group 1, in two animals (28%) of group 2, and in one animal (11%) of groups 3 and 4, respectively. Although there was no animal in groups 5 and 6 with normal graft histology after treatment, there were still four (36%) and three (27%) animals, respectively, that were normoglycemic and that had pancreatic grafts with well-preserved islets. CONCLUSIONS From these data, we conclude that even GIII rejection with severe endothelialitis and isleitis can be reversed. Therefore, we suggest that a trial of enhanced immunosuppression is justified in patients with advanced pancreas allograft rejection.
Collapse
Affiliation(s)
- A Königsrainer
- Department of Transplant Surgery, University of Innsbruck, Austria
| | | | | | | | | | | |
Collapse
|
34
|
Jones JW, Mizrahi SS, Bentley FR. Success and complications of pancreatic transplantation at one institution. Ann Surg 1996; 223:757-62; discussion 762-4. [PMID: 8645049 PMCID: PMC1235227 DOI: 10.1097/00000658-199606000-00014] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
OBJECTIVE The authors report the results and complications of the first 59 pancreas transplantation procedures performed at one institution. SUMMARY BACKGROUND DATA Pancreas transplantation is performed at relatively few centers. Results have improved in the past few years. METHODS A retrospective review was completed of the results and complications after pancreas transplantation at one institution. Pancreas transplantation was indicated for patients with insulin-dependent diabetes mellitus and who were younger than 50 years of age. The results were divided into era I (March 1987-December 1992) and era II (January 1993-October 1995). RESULTS Fifty-nine transplants were performed since March 1987. There were 45 combined kidney/pancreas transplants and 13 pancreas transplants. Graft survival at 1 year was 57% for those in era I versus 79% in era II. Rejection occurred in 74% of the patients in era I and 48% in era II. Eighty-five percent of all rejection episodes in both eras were steroid resistant and required antibody therapy. Complications were not different from eras I and II. CONCLUSIONS Pancreas transplantation is a successful procedure with a number of significant complications. Rejection episodes are most often steroid resistant.
Collapse
Affiliation(s)
- J W Jones
- Department of Surgery, University of Louisville School of Medicine, Kentucky, USA
| | | | | |
Collapse
|
35
|
PANCREAS TRANSPLANTATION. Immunol Allergy Clin North Am 1996. [DOI: 10.1016/s0889-8561(05)70249-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
36
|
PANCREAS TRANSPLANTATION. Radiol Clin North Am 1996. [DOI: 10.1016/s0033-8389(22)00214-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
37
|
Pirsch JD, Andrews C, Hricik DE, Josephson MA, Leichtman AB, Lu CY, Melton LB, Rao VK, Riggio RR, Stratta RJ, Weir MR. Pancreas transplantation for diabetes mellitus. Am J Kidney Dis 1996; 27:444-50. [PMID: 8604718 DOI: 10.1016/s0272-6386(96)90372-8] [Citation(s) in RCA: 37] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
Pancreas transplantation has become a viable option for the patient wi th insulin-dependent diabetes mellitus with progressive renal failure. The most common type of pancreas transplantation is a simultaneous pancreas and kidney transplantation performed from a single cadaver donor (SPK). The next most common is pancreas transplantation after successful kidney transplantation (PAK). A few centers are performing pancreas transplantation alone (PTA) in diabetic recipients without renal disease but who have significant complications from their diabetes. Pancreas transplantation is associated with a higher morbidity than kidney transplantation alone. Most pancreas transplantation centers report a significant increase in acute rejection, which can lead to increased hospitalization and risk of opportunistic infection. In addition, the early era of pancreas transplantation was associated with significant surgical complications. However, with bladder drainage of the pancreas exocrine secretions, the surgical complication rate has decreased significantly. Despite medical and surgical complications, the overall results for pancreas transplantation are excellent, with 1 -year graft survival of 75% for SPK transplantations and 48% for PAK and PTA transplant recipients. The effects of a pancreas transplantation on the secondary complications of diabetes have been studied extensively. Most studies have shown a modest improvement in secondary complications with the exception of diabetic retinopathy. The major benefit of pancreas transplantation appears to be enhanced quality of life for patients successfully transplanted. For these reasons, the Kidney-Pancreas Committee of the American Society of Transplant Physicians believes the current results of pancreas-kidney transplantation justify its use as a valid option for insulin-dependent diabetic transplant recipients.
Collapse
Affiliation(s)
- J D Pirsch
- Department of Surgery, University of Wisconsin Hospital and Clinics, Madison, WI 53792-7375, USA
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Mizrahi SS, Jones JW, Bentley FR. Preparing for Pancreas Transplantation: Donor Selection, Retrieval Technique, Preservation, and Back-Table Preparation. Transplant Rev (Orlando) 1996. [DOI: 10.1016/s0955-470x(96)80001-2] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
39
|
Sutherland DE, Gruessner RW, Gores PF, Brayman K, Wahoff D, Gruessner A. Pancreas transplantation: an update. DIABETES/METABOLISM REVIEWS 1995; 11:337-63. [PMID: 8718495 DOI: 10.1002/dmr.5610110404] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Affiliation(s)
- D E Sutherland
- University of Minnesota Hospital and Clinic, Minneapolis 55455, USA
| | | | | | | | | | | |
Collapse
|
40
|
Sutherland DE, Gruessner RW, Gores PF. Pancreas and islet transplantation: An update. Transplant Rev (Orlando) 1994. [DOI: 10.1016/s0955-470x(05)80036-9] [Citation(s) in RCA: 28] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
41
|
Zehrer CL, Gross CR. Patient perceptions of benefits and concerns following pancreas transplantation. DIABETES EDUCATOR 1994; 20:216-20. [PMID: 7851236 DOI: 10.1177/014572179402000307] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
The purpose of this study was to assess patient perceptions of the impact of pancreas transplantation on various aspects of life, as well as perceptions of the benefits of and concerns with the procedure. All surviving adult patients who had received a pancreas transplant at a midwestern hospital and were at least 1 year posttransplant at the time of the study (N = 138) were sent a self-report questionnaire that included demographic data, questions about life satisfaction, quality of life, symptoms, and health impact. Patients with pancreas graft function reported less pain with healthcare treatment, fewer episodes of feeling physically ill, fewer dietary restrictions, less interference with family life, fewer health limitations in interpersonal relationships and leisure activities, and feeling good about themselves compared with those without graft function. A majority of patients with functioning grafts cited the following benefits: freedom from insulin reactions, normal blood sugars, freedom from insulin injections, freedom from a specialized diet, decreased chance of amputation, feeling better physically, more feelings of hope for the future, and more freedom and control over life. Major concerns posttransplant included side effects and the expense of immunosuppressive medications.
Collapse
|
42
|
Pancreas transplantation — Indications and outcomes. Eur Surg 1994. [DOI: 10.1007/bf02619723] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
43
|
Sutherland DE, Gores PF, Farney AC, Wahoff DC, Matas AJ, Dunn DL, Gruessner RW, Najarian JS. Evolution of kidney, pancreas, and islet transplantation for patients with diabetes at the University of Minnesota. Am J Surg 1993; 166:456-91. [PMID: 8238742 DOI: 10.1016/s0002-9610(05)81142-0] [Citation(s) in RCA: 94] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
Transplantation began at the University of Minnesota in 1963. Treatment of diabetes and its complications has been emphasized since 1966, when the first pancreas-kidney transplant was done. Of 3,640 kidneys transplanted by 1992, 1,373 were for diabetic recipients, including 658 from living donors and 715 from cadaver donors. The results progressively improved; since 1984, survival rates of kidney grafts have been similar for diabetic and nondiabetic recipients, with three fourths of the grafts functioning at 4 years. As of 1992, 501 pancreas transplants had been done, including 170 simultaneous with a kidney, 142 after a kidney, and 188 alone for nonuremic diabetic patients; again, the results have improved: by the 1990s, graft survival rates were similar in the 3 recipient categories. Successful pancreas transplants have been shown by our coworkers to stabilize or improve neuropathy and prevent recurrence of diabetic nephropathy in kidney grafts. In an attempt to simplify endocrine replacement therapy, we have done 63 human islet transplants, 34 as allografts for patients with type I diabetes and 29 as autografts after total pancreatectomy to treat chronic pancreatitis. Insulin independence occurs for about 50% of islet autograft recipients. Two recent islet allograft recipients treated with 15-deoxyspergualin have had sustained insulin independence. We anticipate that endocrine replacement therapy by transplantation will become routine for diabetic patients as methods to prevent rejection are refined.
Collapse
Affiliation(s)
- D E Sutherland
- Department of Surgery, University of Minnesota, Minneapolis
| | | | | | | | | | | | | | | |
Collapse
|
44
|
Hering BJ, Browatzki CC, Schultz A, Bretzel RG, Federlin KF. Clinical islet transplantation--registry report, accomplishments in the past and future research needs. Cell Transplant 1993; 2:269-82; discussion 283-305. [PMID: 8162271 DOI: 10.1177/096368979300200403] [Citation(s) in RCA: 79] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023] Open
Abstract
This review provides the results of a recent analysis of the Islet Transplant Registry on clinical adult islet transplants performed worldwide through June 30, 1992. Between December 12, 1893 and June 30, 1992, 167 adult islet transplants were performed at 25 institutions worldwide, including 104 at 9 institutions in North America, 62 at 15 institutions in Europe, and 1 elsewhere. The total number of diabetic patients reported to be insulin independent after adult islet allotransplantation through June 30, 1992, was 19. In an analysis by era, the percentage of patients that showed positive basal C-peptide levels (i.e., > or = 1 ng/mL at > or = 1 mo) posttransplant, and that became insulin independent (> 1 wk) in the 1985-1989 era (n = 35 cases) were 20% and 6%, and in the 1990-1992 era (n = 69 cases) were 64% and 20%, respectively, and thus have improved significantly (p < 0.001 and p < 0.05). For the 1990-1992 period, the percentage of patients who showed positive basal C-peptide levels post-transplant, and who became insulin independent in the single donor pancreas group (n = 31 cases) were 52% and 13%, and in the multiple donor pancreata group (n = 36 cases) were 75% and 28%, respectively. Islet graft function rates were nearly identical for grafts prepared from pancreata stored < or = 6 h (n = 27) and > 6 < or = 12 h (n = 29), so that 67% and 72% showed positive basal C-peptide levels, and 30% and 21% of the recipients became insulin independent, respectively. No single patient showed islet graft function sufficient to allow withdrawal from insulin, if the pancreata have been stored for more than 12 h. In regard to recipient category for the six groups, namely IAK (islet after kidney), SIK (simultaneous islet kidney transplantation), SIL (simultaneous islet liver transplantation), SIL(C) (simultaneous islet liver transplantation after cluster operation), SIKL (simultaneous islet kidney liver transplantation), and SIH-L (simultaneous islet heart-lung transplantation), the number of patients who showed positive basal C-peptide levels post-transplant was 11 (58%), 17 (57%), 5 (83%), 8 (80%), 1 (50%), and 0 (0%), and the number of insulin independent patients was 4 (21%), 4 (13%), 0 (0%), 6 (60%), 0 (0%), and 0 (0%), respectively. Comparing the two largest recipient categories, namely IAK and SIK, no difference in the outcome of these transplants was apparent.(ABSTRACT TRUNCATED AT 400 WORDS)
Collapse
Affiliation(s)
- B J Hering
- Department of Medicine, Justus-Liebig-University, Giessen, Germany
| | | | | | | | | |
Collapse
|
45
|
Robertson RP. Seminars in medicine of the Beth Israel Hospital, Boston: Pancreatic and islet transplantation for diabetes--cures or curiosities? N Engl J Med 1992; 327:1861-8. [PMID: 1448124 DOI: 10.1056/nejm199212243272607] [Citation(s) in RCA: 65] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Affiliation(s)
- R P Robertson
- Diabetes Center, University of Minnesota Medical School, Minneapolis 55455
| |
Collapse
|
46
|
|
47
|
|
48
|
Affiliation(s)
- P J Lefèbvre
- Department of Medicine, University of Liège, Belgium
| |
Collapse
|
49
|
Cheung AH, Sutherland DE, Gillingham KJ, McHugh LE, Moudry-Munns KC, Dunn DL, Najarian JS, Matas AJ. Simultaneous pancreas-kidney transplant versus kidney transplant alone in diabetic patients. Kidney Int 1992; 41:924-9. [PMID: 1513114 DOI: 10.1038/ki.1992.141] [Citation(s) in RCA: 52] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
The decision for simultaneous pancreas-kidney (SPK) versus kidney transplant alone (KTA) in diabetic patients with renal failure depends on the potential risks and benefits for each procedure. The purpose of this study was to compare the morbidity, mortality, and renal allograft survival in diabetic patients who underwent SPK versus KTA, and to discern the added risks associated with pancreas transplantation. Between 7/1/86 and 9/30/90, 69 primary cadaver SPK and 59 primary cadaver KTA were performed in type I diabetic patients with chronic renal failure. Antilymphocyte globulin or OKT3 was used for induction therapy, followed by standard triple therapy (prednisone, azathioprine, and cyclosporine). Patient and graft survivals were retrospectively analyzed. In addition, a detailed comparison of morbidity in those patients treated after 7/1/87 was performed (53 SPK, 49 KTA). For those less than 45 years of age (65 SPK, 42 KTA), there were no significant differences (P greater than 0.6) in the actuarial patient survival at one year (SPK 92%, KTA 95%), or two years (SPK 89%, KTA 92%), or actuarial renal allograft survival at one year (SPK 82%, KTA 83%) or two years (SPK 77%, KTA 83%). However, for those greater than 45 years old, actuarial renal allograft survival was significantly higher (P less than 0.03) in the KTA group. The mean serum creatinine levels were similar at one year (SPK 1.8, KTA 1.9 mg/d).(ABSTRACT TRUNCATED AT 250 WORDS)
Collapse
Affiliation(s)
- A H Cheung
- Department of Surgery, University of Minnesota, Minneapolis
| | | | | | | | | | | | | | | |
Collapse
|
50
|
Affiliation(s)
- D E Sutherland
- Department of Surgery, University of Minnesota Hospital, Minneapolis 55455
| |
Collapse
|